Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 135

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 135
---
             |    (668,255 | ) |     |       |   (668,255 | ) |
| Balance September 30, 2024 (As Restated)         |     |                    | 10,123,771 |     | $      | 1,011 |     |                     | 34 |     | $      | - |     |                     | 15,007 |     | $      | 2 |     |        | 5,258,235 |     | $      | 527 |     |                    | 29,338 |     | $      | 3 |     | $                  | 15,403,050 |   |     | $                               | (204,847 | ) |     | $           | (20,417,118 | ) |     | $     | (5,217,372 | ) |

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

| 109 |

<div align='center'>REGEN BIOPHARMA , INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS</div>

| CASH FLOWS FROM OPERATING ACTIVITIES                                        |     | 2024                
 Years               
 Ended September 30, 
 2024                
 (As Restated)       |          |   |     | 2023 
 2023 |            |   |
|:----------------------------------------------------------------------------|:----|:--------------------|---------:|:--|:----|:-----|-----------:|:--|
| Net Income (loss)                                                           |     | $                   | (668,255 | ) |     | $    |  1,156,507 |   |
| Adjustments to reconcile net loss to net cash used in operating activities: |     |                     |          |   |     |      |            |   |
| Common Stock issued for Expenses                                            |     |                     |  145,500 |   |     |      |    250,000 |   |
| Preferred Stock issued as compensation                                      |     |                     |   13,048 |   |     |      |    348,372 |   |
| Common Stock issued for Compensation                                        |     |                     |   37,463 |   |     |      |          - |   |
| Interest expense